Redox cofactor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-10. Numbers and descriptions here follow the published literature rather than marketing material.
Measuring NAD+ in biological samples requires care because the molecule is chemically reactive and present at low concentrations in some tissues. Common approaches include enzymatic cycling assays, high-performance liquid chromatography, and liquid chromatography coupled to mass spectrometry. Each method has different sensitivity and specificity, and sample preparation can affect results. Acidic or alkaline extraction steps are used in some protocols, but the choice depends on the analyte and matrix. No single method is universally optimal for every tissue or fluid.
Solid NAD+ is relatively stable when kept dry, cold, and protected from light. Aqueous solutions are more vulnerable to hydrolysis and can lose activity during repeated freeze-thaw cycles or prolonged storage at ambient temperature. Stability depends on pH, ionic strength, and the presence of degrading enzymes or metal ions. For many laboratory uses, aliquots are stored frozen and thawed only once. Exact degradation rates vary by matrix, so stability should be checked for each application rather than assumed.
Beyond redox chemistry, NAD+ acts as a substrate for several enzyme families. ADP-ribosyltransferases, sirtuins, and CD38 ectoenzymes cleave the molecule into nicotinamide and ADP-ribose or related products. These reactions connect NAD+ availability to processes such as DNA repair, chromatin modification, and calcium signaling. Because the coenzyme is used in both electron transfer and signaling, cells maintain separate pools in compartments including the cytosol, mitochondria, and nucleus. The relative sizes and regulation of those pools remain active areas of study.
Cells produce NAD+ through several biosynthetic routes. The salvage pathway recycles nicotinamide, while the Preiss-Handler pathway uses nicotinic acid, and a de novo route can start from tryptophan in some organisms. In mammals, the salvage pathway is generally considered the main source under ordinary conditions. Tissue concentrations vary widely by cell type and compartment, and measured declines with age have been reported in some studies. Whether such changes drive aging or mainly accompany it remains an open question.
| Property | Value | Notes |
|---|---|---|
| UV absorbance maximum | ~259 nm | Nicotinamide ring; spectrum depends on pH. |
| Primary analytical method | LC-MS | Separates and identifies nucleotides with high specificity. |
| Alternative method | Enzymatic cycling | Amplifies signal for low-abundance samples. |
| Typical storage | −20 °C or below | Dry powder, desiccated and protected from light. |
| Degradation products | Nicotinamide and ADP-ribose | Hydrolysis products can interfere with assays. |
Commercial NAD+ is supplied as a solid, often as the free acid or a salt, and purity is verified by chromatographic methods. Laboratories typically store it desiccated at minus 20 degrees Celsius or below. Working solutions are prepared fresh because even sterile aqueous solutions can lose activity over hours to days depending on pH and temperature. Documentation may include a certificate of analysis, an assay value, and a recommended retest date. Researchers should verify identity and purity when results depend on precise cofactor concentrations.
NAD+ is commonly measured by high-performance liquid chromatography with ultraviolet detection, often at 254 or 260 nm. Enzymatic cycling assays provide higher sensitivity by coupling NAD+ to a reporter reaction. Mass spectrometry can distinguish NAD+ from close analogues and confirm isotope labeling. Sample preparation usually involves rapid quenching of metabolism to prevent interconversion with NADH. Because NAD+ and NADH differ by one hydride, extraction conditions strongly affect the measured ratio.
In aqueous solution, NAD+ is most stable under mildly acidic to neutral conditions and degrades faster at high pH or elevated temperature. The molecule can hydrolyze at the pyrophosphate bond or undergo nonenzymatic cyclization. Buffers, chelating agents, and cold temperatures slow these losses during analysis. Repeated freeze-thaw cycles are generally avoided because they can promote degradation and concentration changes. Light exposure is also controlled, though NAD+ is less photolabile than some related nucleotides.
The nicotinamide ring undergoes reversible reduction at the para position, converting NAD+ to NADH. This reaction transfers a hydride equivalent, not a free hydrogen atom or electron alone. Because the redox pair has a defined reduction potential, it links oxidation of fuels to respiratory chain activity. Many dehydrogenases use NAD+ as a co-substrate and produce NADH. The ratio of NAD+ to NADH reflects metabolic state and influences flux through several pathways.
NAD+ also serves as a substrate for enzymes that cleave it, including sirtuins, PARPs, and CD38. These enzymes consume NAD+ and release nicotinamide and ADP-ribose or related products. The dual roles as redox cofactor and signaling substrate connect NAD+ to DNA repair, circadian regulation, and calcium signaling. Cellular NAD+ concentrations vary by tissue, time of day, and stress exposure. How these consumption pathways interact with redox balance remains an active area of research.
Myozyme costs an average of US$300,000 a year and must be taken for the patient's entire life, so some American health insurers have refused to pay for it. In August 2006, Health Canada approved Myozyme for the treatment of Pompe disease. In June 2007, the Canadian Common Drug Review issued its recommendations regarding public funding for Myozyme therapy. Their recommendation was to provide funding to treat a tiny subset of Pompe patients (Infants less one year of age with cardiomyopathy). In May 2010, the FDA approved Lumizyme for the treatment of late-onset Pompe disease. Lumizyme and Myozyme have the same generic ingredient (alglucosidase alfa) and manufacturer (Genzyme Corporation). The difference between these two products is in the manufacturing process. Myozyme is made using a 160-L bioreactor, while Lumizyme uses a 4000-L bioreactor. Because of the difference in the manufacturing process, the FDA claims that the two products are biologically different. Myozyme is FDA approved for replacement therapy for infantile-onset Pompe disease. In July 2021, the European Medicines Agency (EMA) recommended the authorization of avalglucosidase alfa. Avalglucosidase alfa (Nexviazyme) was approved for medical use in the United States in August 2021, and in the European Union in June 2022. In December 2022, the EMA recommended the authorization of cipaglucosidase alfa. The approval was given in June 2023. In the EU, the therapy is available to all age groups without restrictions on weight of patients.
UNICEF spokesperson Toby Fricker stated, "There is no safe place for children anywhere across the strip right now." On 19 December, the United Nations stated Gaza was "by far the most dangerous place in the world to be a child". James Elder, a UNICEF spokesperson, called the conflict in Gaza a "war on children." On 6 January 2024, Tanya Haj-Hassan, a doctor with Doctors Without Borders, stated children in Gaza were "dying in every way possible." On 18 January 2024, the deputy executive director of UNICEF stated the suffering of children in Gaza were the "most horrific conditions I have ever seen." On 2 February 2024, the UNICEF chair stated, "The situation for children in Gaza grows bleaker every day. The world cannot abandon them." On 5 March, UNICEF called the war on Gaza "a test of human conscience" and stated that the lack of humanitarian aid in the north was worsening children's health situation. Adele Khodr, UNICEF's Middle East regional director, stated on 19 March: "The world’s inaction is shocking as more children succumb to a slow death."
Arthrogryposis (AMC) is congenital joint contracture in two or more areas of the body. It derives its name from Greek, actually meaning 'curving of joints' (arthron, ἄρθρον, 'joint'; grȳpōsis, late Latin form of late Greek grūpōsis, γρυπῶσις, 'hooking'). Children born with one or more joint contractures have abnormal fibrosis of the muscle tissue causing muscle shortening, and therefore are unable to perform active extension and flexion in the affected joint or joints. AMC has been divided into three groups: amyoplasia, distal arthrogryposis, and syndromic (is a syndrome or part of a syndrome). Amyoplasia is characterized by severe joint contractures and muscle weakness. Distal arthrogryposis mainly involves the hands and feet. Types of arthrogryposis with a primary neurological or muscle disease belong to the syndromic group.
=== Terminology === Because of concerns around stigma, and because of a move away from the original theoretical basis for the term (see history), there is ongoing debate about renaming borderline personality disorder. While some clinicians agree with the current name, others argue that it should be changed, since many who are labelled with borderline personality disorder find the name unhelpful, stigmatizing, or inaccurate. Alternative suggestions for names include emotional regulation disorder or emotional dysregulation disorder. Impulse disorder and interpersonal regulatory disorder are other valid alternatives, according to John G. Gunderson of McLean Hospital in the United States. Another term suggested by psychiatrist Carolyn Quadrio is post-traumatic personality disorganization (PTPD), reflecting the condition's status as (often) both a form of chronic post-traumatic stress disorder (PTSD) as well as a personality disorder. However, although many with BPD do have traumatic histories, some do not report any traumatic event, which suggests that BPD is not necessarily a trauma spectrum disorder. The Treatment and Research Advancements National Association for Personality Disorders (TARA-APD) campaigned unsuccessfully to change the name and designation of BPD in DSM-5, published in May 2013, in which the name "borderline personality disorder" remains unchanged, and it is not considered a trauma- and stressor-related disorder.
Sources: en.wikipedia.org
=== Nitrogenase (nitrogen fixation) === The fixation of atmospheric nitrogen is an energy-intensive process, as it involves breaking the very stable triple bond between the nitrogen atoms. The nitrogenases catalyze the process. One such enzyme occurs in Rhizobium bacteria. There are three components to its action: a molybdenum atom at the active site, iron–sulfur clusters that are involved in transporting the electrons needed to reduce the nitrogen, and an abundant energy source in the form of magnesium ATP. This last is provided by a mutualistic symbiosis between the bacteria and a host plant, often a legume. The reaction may be written symbolically as
=== Barrow's microdimensional mastering === The astronomer John D. Barrow of the University of Sussex has hypothesized that there are other stages beyond Type III. These Type IV, V, or even VI civilizations would be able to manipulate cosmic structures (galaxies, galactic clusters, superclusters) and even escape the Big Crunch through holes in space. Barrow also proposes an "anti-Kardashev scale": he observes that humans have found it more cost effective to extend their ability to manipulate their environment to smaller and smaller scales rather than to larger and larger ones. He, therefore, proposes a reverse classification, from Type I-minus to Type Omega-minus:
Rheumatism (from the Ancient Greek ῥεῦμα, rheûma) or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the joints or connective tissue. Rheumatism does not designate any specific disorder, but covers at least 200 different conditions, including arthritis and "non-articular rheumatism", also known as "regional pain syndrome" or "soft tissue rheumatism". There is a close overlap between the term soft tissue disorder and rheumatism. Sometimes the term "soft tissue rheumatic disorders" is used to describe these conditions. The term "Rheumatic Diseases" is used in MeSH to refer to connective tissue disorders. The branch of medicine devoted to the diagnosis and therapy of rheumatism is called rheumatology.
== Distribution among species == Liver glucokinase occurs widely but not universally throughout vertebrate species. The gene structure and amino acid sequence are highly conserved among most mammals (e.g., rat and human glucokinase is more than 80% homologous). However, there are some unusual exceptions: For example, it has not been discovered in cats and bats, though some reptiles, birds, amphibians, and fish have it. Whether glucokinase occurs similarly in the pancreas and other organs has not yet been determined. It has been postulated that the presence of glucokinase in liver reflects the ease with which carbohydrates can be included in the animals' diets.
=== Interwar re-establishment and mobilisation in 1939 === The Territorial Force (TF) was officially reconstituted in 1921 by the Territorial Army and Militia Act 1921 and renamed in October as the Territorial Army (TA). The First-Line divisions (that were created in 1907 or 1908) were reconstituted in that year. The TA's intended role was to be the sole method of expanding the size of the British Armed Forces, when compared to the varied methods used during the First World War including the creation of Kitchener's Army. All TA recruits were required to take the general service obligation: if the British Government decided, territorial soldiers could be deployed overseas for combat that avoided the complications of the TF, whose members were not required to leave Britain unless they volunteered for overseas service. The composition of the divisions was altered, with a reduction in the number of infantry battalions required. There was also a reduced need for cavalry, and of the 55 yeomanry regiments, only the 14 most senior retained their horses. The remaining yeomanry was converted to artillery or armored car units or disbanded. The amalgamation of 40 pairs of infantry battalions was announced in October 1921. As part of the post-war "Geddes Axe" financial cuts, the TA was further reduced in size in 1922: artillery batteries lost two of their six guns, the established size of infantry battalions was cut and ancillary medical, veterinary, signals and Royal Army Service Corps units were either reduced in size or abolished.
Sources: en.wikipedia.org
TCM "holds that the body's vital energy (chi or qi) circulates through channels, called jingluo ("meridians and collaterals"), that have branches connected to bodily organs and functions." Its view of the human body is only marginally concerned with anatomical structures, but focuses primarily on the body's functions (such as digestion, breathing, temperature maintenance, etc.): These functions are aggregated and then associated with a primary functional entity – for instance, nourishment of the tissues and maintenance of their moisture are seen as connected functions, and the entity postulated to be responsible for these functions is xiě (blood). These functional entities thus constitute concepts rather than something with biochemical or anatomical properties. The primary functional entities used by traditional Chinese medicine are qì, xuě, the five zàng organs, the six fǔ organs, and the meridians which extend through the organ systems. These are all theoretically interconnected: each zàng organ is paired with a fǔ organ, which are nourished by the blood and concentrate qi for a particular function, with meridians being extensions of those functional systems throughout the body. Concepts of the body and of disease used in TCM are pseudoscientific, similar to Mediterranean humoral theory. TCM's model of the body is characterized as full of pseudoscience. Some practitioners no longer consider yin and yang and the idea of an energy flow to apply.
There are also small-molecule medications that provide temporary relief. Before Onpattro was released, the treatment options for hATTR were limited. After the approval of Onpattro, the FDA awarded Alnylam with the Breakthrough Therapy Designation, which is given to drugs that are intended to treat a serious condition and are a substantial improvement over any available therapy. It was also awarded Orphan Drug Designations given to those treatments that are intended to safely treat conditions affecting fewer than 200,000 people. Along with Onpattro, another RNA interference therapeutic drug, patisiran, has also been developed, which has the property of inhibiting hepatic synthesis of transthyretin. As a result, target messenger RNA (mRNA) is cleaved by small interfering RNAs coupled to the RNA-induced silencing complex. Patisiran, an RNAi therapeutic drug, uses this process to decrease the production of mutant and wild-type transthyretin by cleaving the 3' untranslated region of transthyretin mRNA. In 2019, the FDA approved the second RNAi therapy, Givlaari (givosiran), used to treat acute hepatic porphyria (AHP). The disease is caused by the accumulation of toxic porphobilinogen (PBG) molecules, which are formed during the production of heme. These molecules accumulate in different organs, and this can lead to the symptoms or attacks of AHP. Givlaari is an siRNA drug that downregulates the expression of aminolevulinic acid synthase 1 (ALAS1), a liver enzyme involved in an early step in heme production.
=== Musculoskeletal symptoms === Joint instability and soft tissue injuries: Dislocations, subluxations, or damage to muscles, ligaments, tendons, synovium, or cartilage as a result of excessive joint movement. Chronic pain: Recurrent joint pain that can develop into hyperalgesia, with a higher rate of small fiber neuropathy in some individuals. Disturbed proprioception: Reduced proprioception and muscle weakness, creating a cycle of increasing activity limitations
=== Hyperinsulinemic hypoglycemia === Some mutations have been found to enhance insulin secretion. Heterozygosity for gain of function mutations reduces the threshold glucose that triggers insulin release. This creates hypoglycemia of varying patterns, including transient or persistent congenital hyperinsulinism, or fasting or reactive hypoglycemia appearing at an older age. The most recent overview of GCK mutation that were observed in patients claimed 17 GCK mutations to cause hyperinsulinemic hypoglycemia. Homozygosity for gain of function mutations has not been found.
Sources: en.wikipedia.org
Common laboratory methods include enzymatic cycling, high-performance liquid chromatography, and liquid chromatography with mass spectrometry. The choice depends on sample type, expected concentration, and available equipment.
Frozen storage slows hydrolysis and other degradation reactions that occur more quickly in solution at warmer temperatures. Dry powder is generally more stable than aqueous solutions, which can lose activity over time.
Purity tests can reveal related nucleotides, water content, counterions, and other impurities that may affect an experiment. They do not by themselves establish biological activity or suitability for a specific assay.
NAD+ is a coenzyme found in living cells and is the oxidized form of nicotinamide adenine dinucleotide. It accepts electrons in redox reactions and also serves as a substrate for certain signaling and repair enzymes.